Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
Caroline Holm Nørgaard, Sarah Friedrich, Charlotte T. Hansen, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 540
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101882-101882
Open Access | Times Cited: 253
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Jian Sheng Loh, Wen Qi Mak, Li Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 219
Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
Che‐Yuan Wu, Carina Iskander, Christa Wang, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 297-304
Open Access | Times Cited: 76
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Daniel J. Drucker
Diabetes Care (2024)
Open Access | Times Cited: 75
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Jeffrey L. Cummings, Amanda M. Leisgang Osse, Jefferson W. Kinney
Drugs (2023) Vol. 83, Iss. 15, pp. 1387-1408
Open Access | Times Cited: 64
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Amer E. Alkhalifa, Nour F. Al-Ghraiybah, Julia Odum, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16288-16288
Open Access | Times Cited: 58
Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies
Huilin Tang, Hui Shao, C. Elizabeth Shaaban, et al.
Journal of the American Geriatrics Society (2023) Vol. 71, Iss. 7, pp. 2096-2106
Closed Access | Times Cited: 53
Diabetes mellitus—Progress and opportunities in the evolving epidemic
E. Dale Abel, Anna L. Gloyn, Carmella Evans‐Molina, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3789-3820
Closed Access | Times Cited: 33
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Daniel J. Drucker
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 338-353
Open Access | Times Cited: 20
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
A. Y. Kim, Salman Al Jerdi, Ryan B. MacDonald, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 18
Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US
William Yang Wang, QuangQiu Wang, Xin Qi, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 18
Tirzepatide prevents neurodegeneration through multiple molecular pathways
Rosaria Anna Fontanella, Puja Ghosh, Ada Pesapane, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline
Antonio Lardaro, L. Quarta, Stefania Pagnotta, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1750-1750
Open Access | Times Cited: 17
Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases
Wendy Balestri, Ruchi Sharma, Victor Allisson da Silva, et al.
Journal of Neuroinflammation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 16
Mapping the effectiveness and risks of GLP-1 receptor agonists
Yan Xie, Taeyoung Choi, Ziyad Al‐Aly
Nature Medicine (2025)
Closed Access | Times Cited: 15
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Jeffrey L. Cummings, Alireza Atri, Howard Feldman, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 6
Reconsidering the role of blood-brain barrier in Alzheimer’s disease: From delivery to target
João André Sousa, Catarina Bernardes, Sara Bernardo-Castro, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 29
Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis
Alvin Kuate Defo, Veselko Bakula, Alessandro Pisaturo, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 2, pp. 441-462
Open Access | Times Cited: 29
Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases
Elizabeth M. Rhea, Alice Babin, P. C. Thomas, et al.
Tissue Barriers (2023) Vol. 12, Iss. 4
Open Access | Times Cited: 27
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Sydney S. Wilbon, Mikhail G. Kolonin
Cells (2023) Vol. 13, Iss. 1, pp. 65-65
Open Access | Times Cited: 27
Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
Puja Ghosh, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Theranostics (2023) Vol. 13, Iss. 14, pp. 4872-4884
Open Access | Times Cited: 24
Multi-target drugs for Alzheimer's disease
Bengisu Turgutalp, Çağhan Kızıl
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 7, pp. 628-638
Closed Access | Times Cited: 14
Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study
Bowen Tang, Arvid Sjölander, Jonas W. Wastesson, et al.
EClinicalMedicine (2024) Vol. 73, pp. 102689-102689
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top